Tempus Ai, INC

Tempus AI announced robust second quarter 2026 financial results, driven by significant year-over-year revenue growth in both Diagnostics and Data Licensing, leading to an increase in full-year revenue guidance.

Tempus AI, Inc. announced a definitive agreement to merge with Personalis, Inc. in a transaction structured as a two-step merger, with consideration to be paid in Tempus Class A common stock and potentially cash.

Tempus AI announced its definitive agreement to acquire Personalis, Inc. for $1.5 billion, aiming to integrate Personalis's MRD technology into its AI-enabled precision oncology platform.

Tempus AI announced first quarter 2026 financial results, showcasing significant year-over-year revenue growth and increased financial guidance for the full year.

Tempus AI, Inc. reported robust financial results for Q4 and full year 2025, driven by significant growth in diagnostics and data, alongside positive 2026 revenue and Adjusted EBITDA guidance.

Tempus AI announced preliminary unaudited financial results for Q4 and full year 2025, reporting significant revenue growth and record total contract value.

Tempus AI, Inc. announced its Q2 2026 financial results, showcasing a significant increase in total net revenue driven by strong performance in both its Diagnostics and Data and applications segments.

Tempus AI, Inc. announced significant revenue increases and strategic acquisitions in its latest 10-Q filing, alongside new debt financing and ongoing legal challenges.

Tempus AI reports significant revenue growth in Q2 2025, driven by the Ambry Genetics acquisition and increased demand for its genomics and data services, despite continued net losses.

Tempus AI's Q1 2025 revenue surged, fueled by growth in both its Genomics and Data and Services segments, alongside strategic acquisitions.

Tempus AI's third quarter 2024 results show significant revenue growth driven by both genomics and data services, alongside the impact of its recent IPO.

Tempus AI's second quarter 2024 results highlight significant revenue growth and the completion of its initial public offering, alongside strategic investments in technology and research.

Tempus AI, Inc. announced a significant increase in total revenue to $1.27 billion in 2025, alongside a substantial reduction in net losses and improved adjusted EBITDA, driven by strategic acquisitions and strong growth in its Diagnostics and Data and applications product lines.

Tempus AI's 10-K filing highlights its commitment to precision medicine through intelligent diagnostics and the application of artificial intelligence in healthcare.

Andrew Polovin, EVP, Chief Legal Officer of Tempus AI, Inc., received 40,000 shares of common stock on July 29, 2026.

James William Rogers, Chief Financial Officer of Tempus AI, Inc., received 40,000 shares of common stock on July 29, 2026.

Eric P Lefkofsky, CEO and Chairman, a Director and 10% owner of Tempus AI, Inc., sold 250,000 shares of common stock on July 28, 2026.

Tempus AI announced a definitive agreement to acquire Personalis for $1.5 billion, aiming to enhance its oncology diagnostics and biopharma offerings.

Tempus AI announced its agreement to acquire Personalis, Inc., aiming to integrate genomic data and AI-driven insights.

Tempus AI announced its agreement to acquire Personalis, Inc. for $1.7 billion, aiming to integrate Personalis's ultrasensitive molecular residual disease (MRD) testing into its AI-enabled precision oncology platform.

Tempus AI, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to elect directors, ratify auditors, and vote on executive compensation frequency.

Tempus AI, Inc. has adopted Amended and Restated Articles of Incorporation, waiving jury trials for internal actions, opting out of certain dividend restrictions, and bypassing Nevada's interested stockholder statutes.

Tempus AI, Inc. is holding its annual stockholder meeting on May 20, 2025, to elect directors, ratify the appointment of PricewaterhouseCoopers LLP, and approve reincorporation from Delaware to Nevada.

Tempus AI is holding its annual meeting on May 20, 2025, to elect directors, ratify its auditor, and approve a reincorporation from Delaware to Nevada.

Tempus AI is registering the resale of up to 4,843,136 shares of Class A common stock by a selling stockholder, REALM IDx, Inc., following the acquisition of Ambry Genetics Corporation.

Tempus AI, a healthcare technology company, is going public to further its mission of using AI to personalize diagnostics and treatment.

Tempus AI, a healthcare technology company, has filed for an IPO to further its mission of transforming precision medicine through the application of artificial intelligence.

Tempus AI, a healthcare technology company, has filed for an initial public offering, seeking to expand its AI-driven precision medicine platform across various disease areas.

Tempus AI has entered into a Merger Agreement to acquire all outstanding common stock of Personalis, Inc., with consideration to be paid in Tempus Class A Common Stock or a mix of cash and stock.

Tempus AI, Inc. has increased its beneficial ownership in Personalis, Inc. to 14.3% and amended their commercial agreement to allow for further open market share purchases up to 19.99%.

Baillie Gifford & Co has reported beneficial ownership of 8,649,356 shares, representing 4.98% of the common stock of Tempus AI, Inc., as of March 31, 2026.

The Vanguard Group filed an amendment to its Schedule 13G, reporting 0% beneficial ownership in Tempus AI Inc. due to an internal realignment.

ARK Investment Management LLC and Catherine D. Wood have jointly disclosed a 5.44% beneficial ownership stake in Tempus AI, Inc. through a Schedule 13G filing.

Eric Paul Lefkofsky and affiliated entities disclose significant beneficial ownership in Tempus AI, Inc., totaling 24.0% of Class A Common Stock.

Red Sky Ventures LLC and Kimberly Jo Keywell have filed an Amendment No. 3 to Schedule 13G, disclosing a beneficial ownership of 4.7% in Tempus AI, Inc.'s Class A Common Stock as of September 30, 2025.

Baillie Gifford & Co. has filed an amended Schedule 13G, reporting a 5.75% beneficial ownership stake in Tempus AI, Inc.'s Class A Common Stock.